Vol. 22/No. 19 | OncologyLive

Investigators Aim to Fill Unmet Need of Intermediate- to High-Risk MDS With ENHANCE Trial

October 14, 2021

The initiation of the phase 3 ENHANCE trial looks to build on the generally early response to azacitidine with the addition of magrolimab, a first-in-class monoclonal antibody, for patients with intermediate-, high-, and very high–risk myelodysplastic syndrome.

IO Combo Anchors a New Front Line Taking Shape in Unresectable HCC

October 13, 2021

The tide is starting to turn toward more effective frontline systemic therapies for patients with unresectable hepatocellular carcinoma as a result of the introduction of a novel immune-oncology combination.

Challenges to Scientific Expertise: Future Implications for Oncology

October 12, 2021

The continued uncertainties of the current and future status of the COVID-19 pandemic have resulted in a lack of trust in the authority of the scientific establishment in the United States, and elsewhere, as it operates during these difficult times.